Background-With wide availability of low-cost generics, primary prevention with statins has become less expensive. We projected the cost-effectiveness of expanded statin prescribing strategies using low-cost generics and identified conditions under which aggressive prescribing ceases to be cost-effective. Methods and Results-We simulated expanded statin prescribing strategies with the coronary heart disease policy model, a
C oronary heart disease (CHD) is the leading cause of death in the United States. 1 Statins lower low-density lipoprotein (LDL) cholesterol levels and reduce CHD events and mortality. 2, 3 More widespread use of statins could have a large impact on morbidity and mortality in the United States, 4 but their use has been limited by concerns about their effectiveness, potential side effects, and costs 4 -9 in persons at low short-term risk of CHD.
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As evidence of statin efficacy in lower-risk populations accumulates 10 and statin prices decline, expansion of statin prescribing guidelines may become reasonable. Prior analyses suggest, for example, that when statins cost less than $0.67 per pill, it may be cost-effective to treat all persons with LDL Ͼ130 mg/dL. 4 Because the benefits of treating lower-risk persons are smaller, however, uncertainties regarding adverse effects and quality of life associated with statin use are of greater concern.
No prior analysis has explored how these factors might limit statin prescribing in the current era of low-cost statins.
We used an established computer simulation model to project event rates, costs, and cost-effectiveness of more aggressive statin treatment guidelines that target patients with lower CHD risk and/or lower LDL cholesterol levels. We sought to identify the broadest treatment strategies possible that would be cost-effective or even cost-saving, and then conducted extensive sensitivity analyses to determine what factors might limit an expansion of statin indications under the assumption of universal access to low-cost generic statins.
pressure, smoking status, high-density lipoprotein cholesterol, LDL cholesterol, diabetes mellitus, and use of statin therapy. We modeled statin efficacy via a reduction in LDL cholesterol, an approach that closely replicates the reduction in coronary events with statins 12 and approximates the cost-effectiveness ratios of individual trials 6, 7 when their outcomes data are used. Costs and quality-adjusted life-years (QALYs) were discounted at 3%/y.
Statin Therapy Assumptions
We modeled a low-intensity statin intervention that reduced LDL by 27% (Table 1) , 13, 14 which translates into an 8% to 34% relative risk reduction depending on age (see the online-only Data Supplement). We assumed that monitoring would add 1 lipid panel and physician visit annually. Side-effect rates were derived from systematic reviews of statin trials. 16, 18 Costs of hospitalization for acute kidney failure (from rhabdomyolysis) and liver failure were derived from the Healthcare Cost and Utilization Project, 21 and we assumed a recovery period after myopathy (with or without rhabdomyolysis) or acute liver failure of 30 days with a utility of 0.8 on those days, estimated on the basis of clinical judgment (Table 1) . 15, 19, 20 Diabetes mellitus was assumed to develop at an increased incidence during the first 4 years of statin therapy, 17 with its consequences modeled via increased rates of incident CHD and of non-CHD mortality and costs (see the online-only Data Supplement).
Statin Prices
Statin prices vary dramatically by setting, but low-intensity generic statins are now widely available from discount retailers. For this analysis, we started with the assumption of universal access to statins at $4/mo (as available from Walmart, Target, and many grocers) and explored the limits of statin prescribing under this assumption.
Comparing Lipid-Lowering Interventions
We considered different LDL cholesterol prescribing thresholds (Ͼ160, Ͼ130, and Ͼ100 mg/dL and treat all) for 4 CHD risk groups 22 : moderately high risk (Ն2 risk factors and 10% to 20% 10-year CHD risk), moderate risk (Ն2 risk factors and Ͻ10% 10-year CHD risk), lower risk (1 risk factor), and lowest risk (0 risk factors). Additional analyses included very-low-risk groups such as women 35 to 44 years of age without risk factors.
For each risk group, we identified LDL thresholds at which treatment was incrementally cost-savings or cost-effective compared with treating at the next higher LDL level. Using these thresholds, we created a cost-saving strategy, which treated the largest population possible at LDL thresholds that are cost-saving for each CHD risk group. We then created a maximum impact strategy, which treated the largest population possible at LDL thresholds that are cost-effective for each risk group, defined by an incremental cost-effectiveness ratio less than $50 000/QALY. Costs, event rates, and incremental cost-effectiveness of these strategies were then compared with current treatment and with full implementation of Adult Treatment Panel III guidelines (ATPIII). 22 All simulations also include full implementation of aggressive lipid lowering for secondary prevention and high-risk patients with vascular disease, diabetes mellitus, or 10-year CHD risk Ͼ20%, as per current guidelines. 4, 22 
Sensitivity Analyses
We assessed the impact of potential adverse effects by modeling increased rates of myopathy, hepatitis, and diabetes mellitus (see the online-only Data Supplement for definitions). Alternative diabetes scenarios tested a larger increase in incidence during the first 4 years of statin therapy, as well as an increased incidence over the full 30-year course of statin therapy. We modeled a general disutility 4,23 measured in terms of the average number of days of perfect health that a patient would trade away in exchange for avoiding 30 years of statin therapy. Finally, we modeled 3 hypothetical adverse effect scenarios of varying severity with a range of mortality rates, sick days with reduced quality of life, and hospital days with reduced quality of life and additional costs. The most severe of these hypothetical effects was designed to simulate occurrence of an aggressive cancer caused by statins. Other sensitivity analyses addressed lower levels of statin efficacy and adherence (see the online-only Data Supplement for details).
Analysis
We calculated the incremental cost-effectiveness ratio as additional total healthcare system costs divided by the QALYs gained from 2010 to 2040, presented as annual averages over that time frame. Monte Carlo simulations (nϭ1000) were used to obtain SEs for each base-case CI indicates confidence interval; LDL-C, low-density lipoprotein cholesterol. *For purposes of Monte Carlo simulations (distribution assumptions are given in the online-only Data Supplement), except diabetes mellitus, for which confidence interval was tested in sensitivity analyses.
†Statin efficacy was derived from the average efficacy of low/moderateintensity statins (fluvastatin 40 mg, lovastatin 20 mg, pravastatin 20 mg, simvastatin 10 mg).
‡Detailed definitions are given in the online-only Data Supplement. §On the basis of clinical judgment.
Derived from the Resource-Based Relative Value Scale (with 2006 multiplier) 20 ; 95% CI determined by clinical judgment.
estimate given the uncertainty in our input parameters (see Table 1 and the online-only Data Supplement).
Results

Incremental Cost-Effectiveness of Lowering Low-Density Lipoprotein Thresholds
Primary prevention with statins at $4/mo was projected to be cost-saving in persons with LDL Ͼ100 mg/dL and moderately high risk, with LDL Ͼ130 mg/dL and moderate risk, and with LDL Ͼ160 mg/dL and lower or lowest risk (Table 2) ; these treatment thresholds therefore make up a cost-saving strategy. Treatment was projected to be cost-effective for all patients with moderately high or moderate risk, with LDL Ͼ100 mg/dL and lower risk, and with LDL Ͼ130 mg/dL and lowest risk; these treatment thresholds therefore make up a maximum-impact strategy.
Further evaluation of low-risk subgroups projected that women 35 to 55 years of age with no risk factors would be treated cost-effectively at an LDL threshold of Ͼ160 mg/dL (compared with LDL Ͼ190 mg/dL). Other low-risk groups such as men 35 to 44 years of age were estimated to fall within the cost-effective thresholds identified above.
Impact of the Cost-Saving and Maximum-Impact Strategies
The cost-saving strategy would treat an additional 17 million people per year with statins at an estimated average savings of $1.4 billion per year over the 30 years from 2010 to 2040, after accounting for costs saved from preventing CHD events, compared with current levels of treatment (Table 3 ) and would prevent 14 000 CHD deaths per year. Full implementation of a maximum-impact strategy compared with current levels of treatment would start statin No. started on statins *** ϩ17 000 000 ϩ64 000 000 *** ϩ7 300 000 ϩ55 000 000 MI, n ‡ 700 000 Ϫ30 000 (2800) Ϫ56 000 (1300) 690 000 Ϫ16 000 (1900) Ϫ41 000 (3100) CHD death, n ‡ 430 000 Ϫ14 000 (1200) Ϫ27 000 (2000) 420 000 Ϫ7500 (870) Ϫ20 000 (1400)
Total death, n ‡ 2 300 000 Ϫ12 000 (1000) Ϫ22 000 (1700) 2 300 000 Ϫ6000 (540) Ϫ16 000 (1200) QALY gained *** ϩ130 000 (18 000) ϩ220 000 (31 000) *** ϩ65 000 (9200) ϩ160 000 (22 000)
Cost, $ *** Ϫ1 400 000 000 (400 000 000) ϩ620 000 000 (600 000 000) *** Ϫ430 000 000 (190 000 000) 1 600 000 000 (400 000 000)
ICER, $/QALY *** Cost saving 2800 (2900) *** Cost saving 9900 (3300)
RF indicates risk factor; MI, myocardial infarction; CHD, coronary heart disease; QALY, Quality-adjusted life-year; ICER, incremental cost effectiveness ratio; and ATPIII, Adult Treatment Panel III guidelines.
*Cost-saving strategy would initiate statin therapy for any person not currently taking a statin with low-density lipoprotein cholesterol (LDL) higher than the given thresholds in each risk group: 2 RF and 10 -20% risk: Ͼ100 mg/dl; 2 RF and 0 -10% risk: Ͼ130 mg/dl; 1 RF: Ͼ160 mg/dl; 0 RF: Ͼ160 mg/dl. Treatment according to these thresholds would save money in each risk group. †Maximum-impact strategy would initiate statin therapy for any person not currently taking a statin with LDL higher than the given thresholds in each risk group: 2 RF and 10 -20% risk: Treat all; 2 RF and 0 -10% risk: Treat all; 1 RF: Ͼ100 mg/dl; 0 RF: Ͼ130 mg/dl. Treatment according to these thresholds would cost Ͻ$50,000/QALY in each risk group.
‡Current treatment and ATPIII figures show absolute numbers of MIs, CHD deaths, and total deaths per year, whereas results for the strategies show number events prevented compared with current treatment or ATPIII.
therapy for 64 million persons at an estimated net cost of $620 million per year but would prevent 27 000 CHD deaths per year. Compared with the cost-saving strategy, the maximum-impact strategy would cost $21 000/QALY.
Sensitivity Analysis
The cost-saving strategy remained cost-saving and the maximum-impact strategy remained cost-effective under a broad range of assumptions (Table 4) . Known adverse effects were RF indicates risk factor; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; and ATPIII, Adult Treatment Panel III guidelines. *Cost-saving strategy was designed to save money in each risk group; maximum-impact strategy was designed to be cost-effective at Ͻ$50 000/QALY in each risk group (Table 2) .
†ICERs compare the given strategy with either current levels of treatment or ATPIII (simulating full compliance with current ATPIII). ‡Increase in diabetes mellitus from statin therapy is modeled as capped with increased incidence over the first 4 years of therapy or as persistent with increased incidence for the entire duration of therapy.
§Disutility estimates the number of days of life a person would trade in exchange for not having to take a statin for 30 years.
Reduced statin efficacy is modeled by reducing the effect on LDL reduction but maintaining the same costs and side effects as the base case. ¶Nonadherence is modeled by reducing statin costs, adverse effects, and relative risk reduction proportionate to adherence. Fully nonadherent patients were assumed to have 1 extra physician visit and lipid panel for every 15 person-years of follow-up.
weak drivers of cost-effectiveness, and results were insensitive to even 10-fold increases in myopathy or hepatitis. Results were also insensitive to increases in the rate of statin-induced diabetes mellitus and the duration of the effect (capped at 4 years or persistent over 30 years). If the rate is both persistent over 30 years and increased nearly 5-fold (to 460 per 100 000 personyears), the maximum-impact strategy ceases to be cost-effective compared with ATPIII.
Hypothetical adverse effects of long-term statin use would have to be very common or very severe to make either statin prescribing strategy not cost-effective compared with ATPIII ( Figure 1 ). For example, hypothetical adverse effect 1 would have to occur at an excess rate of 890 cases per 100 000 person-years (equivalent to 27% cumulative incidence over 30 years) to raise the incremental cost-effectiveness ratio for the maximum-impact strategy above $50 000/QALY compared with ATPIII. Adverse effect 3 (a simulated aggressive cancer) would have to occur at an excess rate of 160 cases per 100 000 person years (4.8% cumulative incidence over 30 years) to raise the incremental cost-effectiveness ratio above $50 000/QALY.
Results were moderately sensitive to a disutility for taking a pill or for common small side effects (Figure 2) . The cost-saving strategy compared with ATPIII produced a loss of QALYs if a patient would trade away 64 days of perfect health. The maximum-impact strategy compared with ATPIII ceased to be cost-effective at Ͻ$50 000/QALY when 31 days would be traded. When the maximum-impact strategy is compared with the cost-saving strategy-a comparison that examines the lowest-risk groups in the maximum-impact strategy-cost-effectiveness is lost when the patient would trade 17 days of life.
Results were moderately sensitive to statin efficacy; the estimated incremental cost-effectiveness ratio of the maximum-impact strategy compared with ATPIII would rise above $50 000/QALY if statins were Ͻ62% of their assumed efficacy. Cost-effectiveness ratios were insensitive to nonadherence, with minimal changes even at 25% adherence.
Discussion
If statins are widely available for $4/mo and assumptions about their efficacy apply to low-risk subgroups, expanding statin indications for primary prevention beyond current guidelines would be cost-effective, with modest expansions actually saving money by preventing costly CHD events. Full implementation of the cost-saving strategy-the broadest treatment expansion possible with cost-savings for all CHD Figure 1 . Impact of hypothetical adverse effects on costeffectiveness ratio. A, The cost-saving strategy compared with Adult Treatment Panel III guidelines (ATPIII) ceases to be costsaving at incidences of 320, 130, and 64 cases per 100 000 person-years for adverse effects 1, 2, and 3, respectively. B, The maximum-impact strategy compared with ATPIII ceases to be cost-effective (at a willingness-to-pay threshold of $50 000 per quality-adjusted life-year [QALY]) at incidences of 890, 300, and 160 cases per 100 000 person-years for adverse effects 1, 2, and 3, respectively. C, The maximum-impact strategy compared with the cost-saving strategy ceases to be cost-effective at incidences of 500, 170, and 90 cases per 100 000 personyears for adverse effects 1, 2, and 3, respectively. Adverse effect 1 has 10% mortality, 6 days in hospital, and 30 days sick. Adverse effect 2 has 50% mortality, 15 days in hospital, and 90 days sick. Adverse effect 3 has 85% mortality, 30 days in hospital, and 180 days sick.
risk groups-could avert 14 000 CHD deaths per year and save over $1.4 billion a year compared with current levels of treatment. Full implementation of the maximum-impact strategy-the broadest treatment expansion possible with costeffective treatment for all risk groups-could avert 6.3% of all CHD deaths (nearly 4 times the impact of full implementation of ATPIII) in the United States at a favorable costeffectiveness ratio.
Our findings were insensitive to most adverse effect assumptions, including very large increases in statinassociated myopathy and hepatitis rates, but were sensitive to large increases over base-case assumptions in statinassociated diabetes rates when the excess diabetes incidence was assumed to continue throughout the full 30-year treatment course. Uncertainties remain regarding the mechanism, duration, and magnitude of the statin-diabetes effect. Our estimates were conservative in that we assumed the statindiabetes effect offset some of the efficacy of statins, even though our estimate of the efficacy of statins was derived from trials that already include the statin-diabetes effect.
For hypothetical effects of long-term statin therapy, only very common or very severe effects altered our findings.
For example, adverse effect 3, which is approximately as deadly and severe as lung cancer, would have to occur at an excess rate of 4.6% over 30 years (153 per 100 000 person-years) in statin users to shift the cost-effectiveness of the maximum-impact strategy above $50 000/QALY compared with ATPIII. This rate is similar to lung cancer rates attributable to smoking. 24 Our findings were also robust to variations in statin efficacy. For example, in 45 to 54 year olds in our model, a 27-mg/dL reduction in LDL (from low-intensity statins) translates to a 28% reduction in CHD incidence (see the online-only Data Supplement). This effect would have to be reduced to 17% to modify our findings, an estimate that is inconsistent with meta-analyses. 25 Nonadherence and increased lipid monitoring are also unlikely to affect cost-effective statin prescribing. Adherence rates are as low as 25% to 42%, for example, in studies of the elderly. 26, 27 Even with 25% adherence, however, there was minimal impact on cost-effectiveness. Our results were also insensitive to adding lipid panels and physician visits during the first year of therapy (beyond the single additional annual panel and visit in our base case). Substantial costs from unused prescriptions and continued monitoring despite nonadherence or from very frequent monitoring of lipid panels in adherent patients could alter these conclusions.
Our findings were sensitive to estimates of pill burden, a disutility encompassing minor but potentially common adverse effects such as a mild chronic myositis, or the stigma, anxiety, or inconvenience of taking a pill. If the average person would trade away 1 day per year of perfect health, then the maximum-impact strategy ceases to be cost-effective compared with current ATPIII guidelines. Lowest-risk persons would have to trade only 17 days of life over 30 years to lose cost-effectiveness. Although this factor might be ameliorated with time and/or education, the net effect of statins may be net negative in persons who are resistant to taking the medication.
Our projections have important limitations. Our findings are predicated on universal availability of low-price statins. Prices remain higher for generic statins at many retailers and are much higher for newer statins such as rosuvastatin and atorvastatin. It is also important to note that the low generic statin prices we used in this analysis represent only the cost to the consumer and do not account for their possible role as retail loss leaders.
Statin trials provide relatively consistent proof of risk reduction, but there are inconsistencies and gaps in the literature that our analysis cannot fully address. Trials are available for many but not all subgroups of patients, and for only modest durations of therapy. We note specifically that there is an absence of primary prevention trial data in any population as young as 35 years of age. Although secondary prevention studies have included patients as young as 18 years of age with cardiovascular disease, the youngest participants included in a secondary prevention study were 40 years of age, with most being significantly older. Our model assumes that similar relative benefits extrapolate to persons in all risk subgroups, all racial-ethnic groups, and both sexes, and for a 30-year course of therapy. We did not explicitly model statin complications in pregnant or breastfeeding women; such women should not receive statin therapy. There is uncertainty regarding the effect of statins on total death, with a recent meta-analysis finding a relative risk for all-cause mortality of 0.91, but an upper 95% confidence bound of 1.01 28 ; our simulation results, which show only a small relative reduction in total mortality (relative risk, 0.95 to 0.98; see Table 3 ), are consistent with this estimate.
Consistent with past ATP guidelines and meta-analyses, our model also makes the simplifying assumption that statins act solely through a percent reduction in LDL so that the relative risk reduction is proportional to baseline CHD risk and baseline LDL; however, these relationships do not always hold. For example, although certain higher-risk groups (such as patients with heart failure 29, 30 or on hemodialysis 31, 32 ) have not been found to benefit from statin therapy, certain lower-risk groups (such as patients with isolated high C-reactive protein 10 or low high-density lipoprotein 33 ) appear to obtain large benefits. Moreover, trial data do not demonstrate a clear correlation between a reduction in CHD risk and baseline LDL or degree of LDL reduction. 34 An alternative strategy based only on CHD risk might be expected to result in favorable statin cost-effectiveness for very similar subgroups of persons, with the exception of persons with high cholesterol and low short-term risk, such as younger adults; statin therapy in this setting is matter of ongoing debate. 35, 36 Ultimately, we chose to stay within the established framework with which clinicians and policymakers are familiar. 3 For the same reason, the present study uses CHD risk as a guide to treatment as opposed to global cardiovascular disease risk (which also includes stroke, peripheral artery disease, and heart failure), thus providing a more direct comparison with prior guidelines.
For most primary prevention populations in which a trial has or will show statin efficacy, we have shown cost-effectiveness or even cost-savings. As additional data on primary prevention in low-risk populations continue to emerge, our results should reassure policymakers regarding the cost-effectiveness of expanding statin prescribing guidelines. The substantial potential health benefits and savings in healthcare costs from preventing CHD events will need to be weighed against the possibility of adverse effects of long-term statin therapy. Our analysis helps to quantify how large these effects would have to be to negate the cost-effectiveness of aggressive statin prescribing. Future research on statins, in the form of large trials of low-risk persons and postmarketing surveillance, can help to reduce uncertainty about adverse effects, to determine whether the benefits of statins extend to groups not currently well represented in randomized trials, and to understand the challenges of having healthy individuals take a regular preventive medication.
